Crescent Biopharma (FRA:C68) Ending Cash Position: €149.04 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:C68 Crescent Biopharma Inc FRA:C68
18 GF Score
Price €13.50
! 1 Warning Sign
View Full Analysis

What is Crescent Biopharma Ending Cash Position?

Crescent Biopharma FRA:C68 +0.75% 18 Ending Cash Position is €149.04 Mil as of Jun. 2026. GuruFocus rates FRA:C68 with a GF Score™ of 18/100. The stock has 1 warning sign investors should review.

Crescent Biopharma's Ending Cash Position for the quarter that ended in Jun. 2026 was €149.04 Mil.

Crescent Biopharma's quarterly Ending Cash Position declined from Dec. 2025 (€182.16 Mil) to Mar. 2026 (€163.72 Mil) and declined from Mar. 2026 (€163.72 Mil) to Jun. 2026 (€149.04 Mil).

Crescent Biopharma's annual Ending Cash Position stayed the same from . 20 (€0.00 Mil) to Dec. 2024 (€0.00 Mil) but then increased from Dec. 2024 (€0.00 Mil) to Dec. 2025 (€182.16 Mil).

Crescent Biopharma Ending Cash Position Related Terms

Crescent Biopharma Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Crescent Biopharma's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Crescent Biopharma Ending Cash Position Chart

Crescent Biopharma Annual Data
Trend Dec24 Dec25
Ending Cash Position
0.00 182.16

Crescent Biopharma Quarterly Data
Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial 132.44 113.63 182.16 163.72 149.04
FRA:C68
18GF Score
Crescent Biopharma Inc FRA:C68
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Crescent Biopharma Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Crescent Biopharma's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=29.69+152.467
=182.16

Crescent Biopharma's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=164.287+-15.251
=149.04

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of €149.04 Mil mean?
Crescent Biopharma (FRA:C68) has a Ending Cash Position of €149.04 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Crescent Biopharma and its competitors.
Is Crescent Biopharma's Ending Cash Position too high?
Crescent Biopharma's current Ending Cash Position is €149.04 Mil. Overall, Crescent Biopharma has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Crescent Biopharma's Ending Cash Position compare to ALLO and IMMX?
Crescent Biopharma's Ending Cash Position of €149.04 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Crescent Biopharma and its competitors. Crescent Biopharma's current Ending Cash Position is €149.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crescent Biopharma stock overvalued right now?
Crescent Biopharma (FRA:C68) has a current Ending Cash Position of €149.04 Mil. The current Ending Cash Position is €149.04 Mil. Crescent Biopharma's overall GF Score™ is 18/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Crescent Biopharma (FRA:C68), the current Ending Cash Position is €149.04 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Crescent Biopharma Business Description

Other Exchanges CBIO:USA
Address 300 Fifth Avenue, Waltham, MA, USA, 02451
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
18GF Score

Get the complete analysis for FRA:C68

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€13.50
Price